Quick Answer
Fulcrum Therapeutics, Inc. reported Net Income of -$74.88 million for fiscal year 2025.
Fulcrum Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$74.88M -670.0% |
-$9.72M +90.0% |
-$97.33M +11.4% |
-$109.87M -35.9% |
-$80.85M -14.2% |
-$70.82M +14.3% |
| Diluted EPS | -$1.18 -637.5% |
-$0.16 +89.9% |
-$1.59 +34.8% |
-$2.44 -6.6% |
-$2.29 | — |
| Total Assets | $366.28M +40.5% |
$260.72M +1.2% |
$257.69M +13.7% |
$226.69M -3.5% |
$235.00M +81.4% |
$129.58M +17.3% |
| Cash and Equivalents | $197.53M +239.3% |
$58.21M +127.7% |
$25.56M -27.2% |
$35.10M -0.9% |
$35.41M -37.9% |
$57.05M -41.0% |
| Stockholders Equity | $349.00M +43.6% |
$243.03M +3.3% |
$235.19M +18.2% |
$198.94M -6.0% |
$211.54M +122.2% |
$95.18M +9.2% |
| R&D Expense | $56.10M -11.5% |
$63.39M -11.7% |
$71.80M -6.5% |
$76.78M +10.2% |
$69.70M +18.1% |
$59.04M -16.9% |
| Operating Income | -$84.77M -287.1% |
-$21.90M +80.2% |
-$110.66M +1.7% |
-$112.56M -38.9% |
-$81.05M -13.2% |
-$71.61M +15.0% |
| Shares Outstanding | 66.58M +23.4% |
53.97M -12.8% |
61.92M +18.8% |
52.10M +28.2% |
40.63M +45.4% |
27.94M +23.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$19.59M | +9.7% | -13.3% |
| Diluted EPS | September 30, 2025 | -$0.31 | +11.4% | -10.7% |
| Total Assets | September 30, 2025 | $214.86M | -23.0% | -6.1% |
| Cash and Equivalents | September 30, 2025 | $47.08M | -35.2% | +10.5% |
| Stockholders Equity | September 30, 2025 | $198.37M | -22.9% | -7.5% |
| R&D Expense | September 30, 2025 | $14.30M | -2.3% | +10.1% |
| Operating Income | September 30, 2025 | -$21.86M | +13.0% | -10.3% |
| Shares Outstanding | September 30, 2025 | 54.11M | +0.3% | +0.0% |
- Fulcrum Therapeutics, Inc. reported Net Income of -$74.88 million for fiscal year 2025.
- Fulcrum Therapeutics, Inc. showed a decrease of -670.0% in Net Income compared to the prior fiscal year.
- Fulcrum Therapeutics, Inc. reported Diluted EPS of $1.18 per share (loss) for fiscal year 2025.
- Fulcrum Therapeutics, Inc. showed a decrease of -637.5% in Diluted EPS compared to the prior fiscal year.
- Fulcrum Therapeutics, Inc. reported Total Assets of $366.28 million for fiscal year 2025.
- Fulcrum Therapeutics, Inc. showed an increase of +40.5% in Total Assets compared to the prior fiscal year.
- Fulcrum Therapeutics, Inc. reported Cash and Equivalents of $197.53 million for fiscal year 2025.
- Fulcrum Therapeutics, Inc. showed an increase of +239.3% in Cash and Equivalents compared to the prior fiscal year.
- Fulcrum Therapeutics, Inc. reported Stockholders Equity of $349.00 million for fiscal year 2025.
- Fulcrum Therapeutics, Inc. showed an increase of +43.6% in Stockholders Equity compared to the prior fiscal year.
- Fulcrum Therapeutics, Inc. reported R&D Expense of $56.10 million for fiscal year 2025.
- Fulcrum Therapeutics, Inc. showed a decrease of -11.5% in R&D Expense compared to the prior fiscal year.
- Fulcrum Therapeutics, Inc. reported Operating Income of -$84.77 million for fiscal year 2025.
- Fulcrum Therapeutics, Inc. showed a decrease of -287.1% in Operating Income compared to the prior fiscal year.
- Fulcrum Therapeutics, Inc. reported Shares Outstanding of 66.58 million shares for fiscal year 2025.
- Fulcrum Therapeutics, Inc. showed an increase of +23.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: